Treatment patterns and durable response among OligoCD and iMCD subtypes
| . | TAFRO n = 65 . | IPL n = 12 . | NOS n = 42 . | OligoCD n = 14 . | UCD n = 46 . |
|---|---|---|---|---|---|
| No. of regimens administered, median (IQR) | 3 (2-4) | 4 (2.8-5) | 3 (2-4) | 2 (2-3) | 1 (1-2) |
| LN excision (partial or complete) | |||||
| Ever received, n | 11 | 10 | 31 | 14 | 43 |
| Response evaluable, n | 10 | 9 | 25 | 6 | 19 |
| Response ratio (%) | 0/10 (0) | 0/9 (0) | 2/25 (8) | 1/6 (16.7) | 12/19 (63.2) |
| Response unknown, n | 1 | 1 | 6 | 8 | 24 |
| Steroid monotherapy | |||||
| Ever received, n | 27 | 6 | 14 | 2 | 6 |
| Response evaluable, n | 24 | 5 | 10 | 1 | 1 |
| Response ratio (%) | 0/24 (0) | 0/5 (0) | 2/10 (20) | 0/1 (0) | 0/1 (0) |
| Response unknown, n | 3 | 1 | 4 | 1 | 5 |
| Anti–IL-6 w/wo steroids∗ | |||||
| Ever received, n | 39 | 10 | 21 | 2 | 3 |
| Response evaluable, n | 36 | 10 | 16 | 2 | 3 |
| Response ratio (%) | 16/36 (44.4) | 6/10 (60) | 7/16 (43.8) | 1/2 (50) | 1/3 (33.3) |
| Response unknown, n | 3 | 0 | 5 | 0 | 0 |
| Siltuximab ± steroids | |||||
| Ever received, n | 28 | 8 | 20 | 2 | 3 |
| Response evaluable, n | 24 | 8 | 15 | 2 | 3 |
| Response ratio (%) | 11/24 (45.8) | 5/8 (62.5) | 6/15 (40) | 1/2 (50) | 1/3 (33.3) |
| Response unknown, n | 4 | 0 | 5 | 0 | 0 |
| Tocilizumab w/wo steroids | |||||
| Ever received, n | 15 | 4 | 1 | 1 | 0 |
| Response evaluable, n | 14 | 3 | 1 | 1 | 0 |
| Response ratio (%) | 5/14 (35.7) | 2/3 (66.7) | 1/1 (100) | 0/1 (0) | 0 |
| Response unknown, n | 1 | 1 | 0 | 0 | 0 |
| Rituximab w/wo steroids | |||||
| Ever received, n | 12 | 6 | 21 | 4 | 5 |
| Response evaluable, n | 11 | 6 | 12 | 3 | 4 |
| Response ratio (%) | 3/11 (27.3) | 0/6 (0) | 3/12 (25) | 0/3 (0) | 1/4 (25) |
| Response unknown, n | 1 | 0 | 9 | 1 | 1 |
| Chemotherapy w/wo other agents | |||||
| Ever received, n | 29 | 0 | 3 | 2 | 2 |
| Response evaluable, n | 23 | 0 | 2 | 2 | 2 |
| Response ratio (%) | 11/23 (47.8) | 0 | 1/2 (50) | 0/2 (0) | 0/2 (0) |
| Response unknown, n | 6 | 0 | 1 | 0 | 0 |
| Other | |||||
| Ever received, n | 37 | 4 | 10 | 2 | 7 |
| Response evaluable, n | 33 | 4 | 9 | 2 | 4 |
| Response ratio (%) | 14/33 (42.4) | 0/4 (0) | 3/9 (33.3) | 1/2 (50.0) | 2/4 (50) |
| Response unknown, n | 4 | 0 | 1 | 0 | 3 |
| . | TAFRO n = 65 . | IPL n = 12 . | NOS n = 42 . | OligoCD n = 14 . | UCD n = 46 . |
|---|---|---|---|---|---|
| No. of regimens administered, median (IQR) | 3 (2-4) | 4 (2.8-5) | 3 (2-4) | 2 (2-3) | 1 (1-2) |
| LN excision (partial or complete) | |||||
| Ever received, n | 11 | 10 | 31 | 14 | 43 |
| Response evaluable, n | 10 | 9 | 25 | 6 | 19 |
| Response ratio (%) | 0/10 (0) | 0/9 (0) | 2/25 (8) | 1/6 (16.7) | 12/19 (63.2) |
| Response unknown, n | 1 | 1 | 6 | 8 | 24 |
| Steroid monotherapy | |||||
| Ever received, n | 27 | 6 | 14 | 2 | 6 |
| Response evaluable, n | 24 | 5 | 10 | 1 | 1 |
| Response ratio (%) | 0/24 (0) | 0/5 (0) | 2/10 (20) | 0/1 (0) | 0/1 (0) |
| Response unknown, n | 3 | 1 | 4 | 1 | 5 |
| Anti–IL-6 w/wo steroids∗ | |||||
| Ever received, n | 39 | 10 | 21 | 2 | 3 |
| Response evaluable, n | 36 | 10 | 16 | 2 | 3 |
| Response ratio (%) | 16/36 (44.4) | 6/10 (60) | 7/16 (43.8) | 1/2 (50) | 1/3 (33.3) |
| Response unknown, n | 3 | 0 | 5 | 0 | 0 |
| Siltuximab ± steroids | |||||
| Ever received, n | 28 | 8 | 20 | 2 | 3 |
| Response evaluable, n | 24 | 8 | 15 | 2 | 3 |
| Response ratio (%) | 11/24 (45.8) | 5/8 (62.5) | 6/15 (40) | 1/2 (50) | 1/3 (33.3) |
| Response unknown, n | 4 | 0 | 5 | 0 | 0 |
| Tocilizumab w/wo steroids | |||||
| Ever received, n | 15 | 4 | 1 | 1 | 0 |
| Response evaluable, n | 14 | 3 | 1 | 1 | 0 |
| Response ratio (%) | 5/14 (35.7) | 2/3 (66.7) | 1/1 (100) | 0/1 (0) | 0 |
| Response unknown, n | 1 | 1 | 0 | 0 | 0 |
| Rituximab w/wo steroids | |||||
| Ever received, n | 12 | 6 | 21 | 4 | 5 |
| Response evaluable, n | 11 | 6 | 12 | 3 | 4 |
| Response ratio (%) | 3/11 (27.3) | 0/6 (0) | 3/12 (25) | 0/3 (0) | 1/4 (25) |
| Response unknown, n | 1 | 0 | 9 | 1 | 1 |
| Chemotherapy w/wo other agents | |||||
| Ever received, n | 29 | 0 | 3 | 2 | 2 |
| Response evaluable, n | 23 | 0 | 2 | 2 | 2 |
| Response ratio (%) | 11/23 (47.8) | 0 | 1/2 (50) | 0/2 (0) | 0/2 (0) |
| Response unknown, n | 6 | 0 | 1 | 0 | 0 |
| Other | |||||
| Ever received, n | 37 | 4 | 10 | 2 | 7 |
| Response evaluable, n | 33 | 4 | 9 | 2 | 4 |
| Response ratio (%) | 14/33 (42.4) | 0/4 (0) | 3/9 (33.3) | 1/2 (50.0) | 2/4 (50) |
| Response unknown, n | 4 | 0 | 1 | 0 | 3 |
Response assessment was determined according to the change in the proportion of symptoms present before and after a given regimen was initiated. A response was recorded if there was at least 50% improvement in the proportion of symptoms present after a regimen initiation compared with before or at the time of initiation.
w/wo, with/without.
Inclusive of patients ever treated with either siltuximab w/wo steroids and/or tocilizumab w/wo steroids. Best response among those regimens is listed.